The urokinase receptor as a potential target in cancer therapy

Current Pharmaceutical Design

Volumn 10, Issue 19, 2004, Pages 2359-2376

  Rømer, John ^a   Nielsen, Boye Schnack ^a   Ploug, Michael ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

CD87; Peptide antagonists; uPA; uPAR

Indexed keywords

AE 105; AE 120; AE 68; AE 78; ALPHA 2 ANTIPLASMIN; ANTINEOPLASTIC AGENT; CATHEPSIN B; CATHEPSIN K; CYCLOPEPTIDE; CYSTEINE PROTEINASE INHIBITOR; GLYCOLIPID; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTEGRIN; LIGAND; LYSINE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; PROUROKINASE; RECOMBINANT PROTEIN; SAPORIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE RECEPTOR; VITRONECTIN;

ANTINEOPLASTIC ACTIVITY; CANCER INVASION; CANCER THERAPY; COLON CANCER; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; METASTASIS; NONHUMAN; PHENOTYPE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; LIGANDS; NEOPLASM METASTASIS; NEOPLASMS; PEPTIDES; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042743709     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383962     Document Type: Review

References (165)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
2. Danø K, Rømer J, Nielsen BS, Bjørn S, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. Apmis 1999; 107: 120-127.
3. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-442.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev Cancer 2002; 2: 161-174.
5. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-874.
6. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995; 1: 1035-1039.
7. Vassalli JD, Baccino D, Belin DA. cellular binding site for the M(r) 55,000 form ofthe human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92.
8. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proceedings of the National Academy of Sciences of the United States of 1985; 82: 4939-4943.
9. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase- type plasminogen activator. J Biol Chem 1989; 264: 1180-1189.
10. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Danø K, Blasi FA. 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263: 2358-2363.
11. Behrendt N, Rønne E, Ploug M. Petri T, Løber D, Nielsen LS, et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453-6460.
12. Nykjaer A, Petersen CM, Christensen EI, Davidsen O, Gliemann J. Urokinase receptors in human monocytes. Biochim Biophys Acta 1990; 1052: 399-407.
13. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 1989; 264: 2185-2188.
14. Ellis V. Plasminogen activation at the cell surface. Curr Top Dev Biol 2003; 54: 263-312.
15. Ellis V, Danø K. Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost 1991; 17: 194-200.
16. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-303.
17. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-21197.
18. Liu SH, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976-17984.
19. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci USA 2003; 100: 657-662.
20. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333.
21. Netzel-Arnett S, Mitola DJ, Yamada SS, Chrysovergis K, Holmbeck K, Birkedal-Hansen H, Bugge T. H. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem 2002; 277: 45154-45161.
22. Ellis V, Wun TC, Behrendt N, Rønne E, Danø K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 1990; 265: 9904-9908.
23. Nykjaer A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267: 14543-14546.
24. Heegaard CW, Simonsen AC, Oka K, Kjøller L, Christensen A, Madsen B, et al. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 1995; 270: 20855-20861.
25. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, et al. Recycling of tile urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16: 2610-2620.
26. Vilhardt F, Nielsen M, Sandvig K, van Deurs B. Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells. Mol Biol Cell 1999; 10: 179-195.
27. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2: 91-100.
28. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
29. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-14750.
30. Høyer-Hansen G, Behrendt N, Ploug M, Danø K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997; 420: 79-85.
31. Sidenius N, Andolfo A, Fesce R, Blasi F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 2002; 277: 27982-27990.
32. Kjøller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001; 152: 1145-1157.
33. Deng G, Curriden SA, Wang,S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-1571.
34. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol 2003; 160: 781-791.
35. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. Apmis 1999; 107: 54-61.
36. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
37. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999; 144: 1285-1294.
38. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228-10234.
39. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 1999; 146: 149-164.
40. Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 2003; 101: 1582-1590.
41. Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137: 767-777.
42. Aguirre-Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104.
43. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cel 12001; 12: 863-879.
44. Liu D, Aguirre GJ, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1; 445-457.
45. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684-1695.
46. Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002; 20: 2005-2016.
47. Kjøller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002: 383: 5-19.
48. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
49. Ossowski L. Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12: 613-620.
50. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003; 9: 1565-1574.
51. Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue, American Journal of Clinical Pathology 1994; 102: 835-841.
52. Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-1067.
53. Pyke C, Ralfkiaer E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994; 24: 131-138.
54. Ohtani H, Pyke C, Danø K, Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 1995; 62: 691-696.
55. Pyke C, Salo S, Ralfkiaer E, Rømer J, Danø K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995; 55: 4132-4139.
56. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993; 36: 627-635.
57. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003; 46: 1054-1059.
58. Lenander C, Habermann JK, Ost A, Nilsson B, Schimmelpenning H, Tryggvason K, et al. Laminin-5 gamma 2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal Cell Pathol 2001 22: 201-209.
59. Skyldberg B, Salo S, Eriksson E, Aspenblad U, Moberger B, Tryggvason K, et al. Laminin-5 as a marker of invasiveness in cervical lesions. J Natl Cancer Inst 1999; 91: 1882-1887.
60. Pyke C, Graem N, Ralfkiaer E, Rønne E, Høyer-Hansen G, Brünner N, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 1911-1915.
61. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-866.
62. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994; 54: 5016-5020.
63. Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ. Spitz naevi may express components of the plasminogen activation system. J Pathol 2002; 198: 92-99.
64. Migita T, Sato E, Saito K, Mizoi T, Shiiba K, Matsuno S, et al. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Int. J Cancer 1999; 84: 74-79.
65. Morita S, Sato A, Hayakawa H, Hara H, Urano T, Takada Y, et al. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by northern blotting and in situ hybridization. Int J Cancer 1998; 78: 286-292.
66. Borgfeldt C, Hansson SR, Gustavsson B, Masback A, Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 2001; 92: 497-502.
67. Borgfeldt C, Casslen B, Liu CL, Hansson S, Lecander I, Åstedt B. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 1998; 79: 588-595.
68. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol 2000; 190: 190-195.
69. Rømer J, Pyke C, Lund LR, Ralfkinaer E, Danø K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J Invest Dermatol 2001; 116: 353-358.
70. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000; 156: 567-575.
71. Rømer J. Skin cancer and wound healing. Tissue-specific similarities in extracellular proteolysis. APMIS 2003; 111 Suppl. 107: 5-36.
72. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 1994; 102: 519-522.
73. Solberg H, Ploug M, Høyer-Hansen G, Nielsen BS, Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001; 49: 237-246.
74. Nykjaer A, Petersen CM, Møller B, Andreasen PA, Gliemann J. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett 1992; 300: 13-17.
75. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost 1999; 81: 705-710.
76. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000; 60: 7126-7132.
77. Grøndahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991; 138: 111-117.
78. Nielsen BS, Schested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Laboratory Investigation 1996; 74: 168-177.
79. Nielsen BS, Schested M, Duun S, Rank F, Timshe S, Rygaard J, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Laboratory Investigation 2001; 81: 1485-1501.
80. Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997; 150: 1231-1244.
81. Rønnov-Jessen L, van Deurs B, Nielsen M, Petersen O. W. Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In Vitro Cell Dev Biol 1992; 28A: 273-283.
82. Le DM, Besson A, Fogg DK, Choi KS, Waisman DM, Goodyer CG, Rewcastle B, Yong VW. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 2003; 23: 4034-4043.
83. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-402.
84. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-1087.
85. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
86. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8: 1132-1141.
87. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis published erratum appears in EMBO J 1990 May; 9(5): 1674. EMBO J 1990; 9: 467-474.
88. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-1933.
89. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
90. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-1528.
91. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 1994; 349: 163-168.
92. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991; 266: 7842-7847.
93. Ploug M, Kjalke M, Rønne E, Weidle U, Høyer-Hansen G, Danø K. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 1993; 268: 17539-17546.
94. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243: 21-26.
95. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002; 99: 1359-1364.
96. Wahlberg K, Høyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 1998; 58: 3294-3298.
97. Ploug M, Østergaard S, Hansen LB, Holm A, Danø K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998; 37: 3612-3622.
98. Magdolen V, Rettenberger P, Koppitz M, Goretzki L, Kessler H, Weidle UH, et al. Systematic mutational analysis of the receptor-binding region ofthe human urokinase-type plasminogen activator. Eur J Biochem 1996; 237: 743-751.
99. Ploug, M, Rahbek-Nielsen H, Ellis V, Roepstorff P, Danø K. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 1995; 34: 12524-12534.
100. Schmiedeberg N, Schmitt M, Rolz C, Truffault V, Sukopp M, Burgle M, et al. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem 2002; 45: 4984-4994.
101. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proceedings of the National Academy of Sciences of the United States of 1994; 91: 7129-7133.
102. Ploug M, Østergaard S, Gårdsvoll H, Kovalski K, Hoist-Hansen C, Holm A, et al. Peptide-derived antagonists of the urokinase receptor, affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40: 12157-12168.
103. Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33: 8991-8997.
104. Behrendt N, Rønne E, Danø K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996; 271: 22885-22894.
105. Ploug M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in tke assembly ofa composite ligand-binding site. Biochemistry 1998; 37: 16494-16505.
106. Gårdsvoll H, Danø K, Ploug M. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J Biol Chem 1999; 274: 37995-38003.
107. Bdeir K, Kuo A, Mazar A, Sachais BS, Xiao W, Gawlak S, et al. A region in domain II of the urokinase receptor required for urokinase binding. J Biol Chem 2000; 275: 28532-28538.
108. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001; 12: 2975-2986.
109. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277:, 46932-46939.
110. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003; 10: 541-544.
111. Fong S, Doyle MV, Goodson RJ, Drummond RJ, Stratton JR, McGuire L, et al. Random peptide bacteriophage display as a probe for urokinase receptor ligands. Biol Chem 2002; 383: 149-158.
112. van der Pluijm G, Sijmons B, Vloedgraven H, van der BC, Drijfhout JW, Verheijen J, et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001; 159: 971-982.
113. Rockway TW, Giranda VL. Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Des 2003; 9: 1483-1498.
114. Tressler RJ, Pitot PA, Stratton JR, Forrest LD, Zhuo S, Drummond RJ, et al. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. Apmis 1999; 107: 168-173.
115. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.
116. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
117. Ignar DM, Andrews JL, Witherspoon SM. Leray JD, Clay WC, Kilpatrick K. Onori urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis 1998; 16: 9-20.
118. Quax PH, Lamfers ML, Lardenoye JH, Grimbergen JM, de Vries MR, Slomp J, et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 2001; 103: 562-569.
119. Kobayashi H, Sugino D, She MY, Ohi H, Hirashima Y, Shinohara H, et al. Bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 1998; 253: 817-826.
120. Muehlenweg B, Assfalg-Machleidt I, Parrado SG, Burgle M, Creutzburg S, Schmitt M, et al. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J Biol Chem 2000; 275: 33562-33566.
121. Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D, Terao T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 1995; 270: 8361-8366.
122. Fabbrini MS, Carpani D, Bello-Rivero I, Soria MR. The aminoterminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. FASEB J 1997; 11: 1169-1176.
123. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the Urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. J Biol Chem 2000; 275: 7566-7573.
124. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin Fusion protein DTAT. J Natl Cancer Inst 2002; 94: 597-606.
125. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262: 4437-4440.
126. Burgle M, Koppitz M, Riemer C, Kessler H, König B, Weidle UH, et al. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biological Chemistry 1997; 378: 231-237.
127. Magdolen V, Burgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, et al. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001; 382: 1197-1205.
128. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9: 1529-1543.
129. Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett 2002; 528: 212-216.
130. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR- based assay. Cell 1998; 94: 353-362.
131. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-2445.
132. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997; 272: 20456-20462.
133. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999; 17: 177-181.
134. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-1051.
135. Rømer J, Pyke C, Lund LR, Eriksen J, Kristensen P, Rønne E, et al. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 1994; 57: 553-560.
136. Noel A, Hajitou AL, Hoir C, Maquoi E, Baramova E, Lewalle JM, et al. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998; 76: 267-273.
137. Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, et al. Direct evidence of the importance of stromall urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001; 61: 532-537.
138. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998; 140: 1535-1541.
139. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-5847.
140. Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998; 5: 1105-1113.
141. Nielsen BS, Sehested M, Dunn S, Rank F, Timshel S, Rygaard J, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001; 81: 1485-1501.
142. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor Volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 2002; 62: 2390-2397.
143. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
144. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, et al. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16: 3097-3104.
145. Almholt K, Nielsen BS, Frandsen TL, Brünner N, Danø K, Johnsen M. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003; 22: 4389-4397.
146. Nielsen BS, Lund LR, Christensen IJ, Johnsen M, Usher PA, Wulf-Andersen L, et al. A precise and efficient stereological method for determining murine lung metastasis volumes. Am J Pathol 2001; 158: 1997-2003.
147. Lund LR, Rømer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999; 18: 4645-4656.
148. Lu H, Yeh P, Guitton JD, Mabilat C, Desanlis F, Maury I, et al. Blockage of the urokinase receptor on the cell Surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 1994, 356: 56-59.
149. LU H, Mabilat C, Yeh P, Guitton JD, Li H, Pouchelet M, et al.
150. Ballance DJ, Marshall JM, Cottinghana IR, Steven J, Berry SJ, Cederholm-Williams SA, et al. Hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem 1992; 207: 177-183.
151. Rønne F, Behrendt N, Ellis V, Ploug M, Danø K, Høyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-236.
152. List K, Høyer-Hansen G, Rønne E, Danø K, Behrendt N. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods 1999; 222: 125-133.
153. Wilhelm O, Weidle U, Holil S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliteration and invasion of human ovarian cancer cells. FEBS Left 1994; 337: 131-134.
154. Lutz V, Reuning U, Kruger A, Luther T, von Steinburg SP, Graeff H, et al. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001; 382: 789-798.
155. Kruger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD97). Cancer Gene Ther 2000; 7: 292-299.
156. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-3991.
157. Lakka SS, Gondi CS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, et al. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 2003: 63: 2454-2461.
158. Mohan PM, Lakka SS, Mohanana S, Kin Y, Sawaya R, Kyritsis AP, et al. Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells. Clin Exp Metastasis 1999; 17: 617-621.
159. Ippoliti R, Lendaro E, Benedetti PA, Torrisi MR, Belleudi F, Carpani D, et al. Endocytosis of a chimera between human prourokinase and the plant toxin saporin: an unusual internalization mechanism. FASEB J 2000; 14: 1335-1344.
160. Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res 2003; 27: 79-84.
161. Torres AM, Kini RM, Selvanayagam N, Kuchel PW. NMR structure of bucandin, a neurotoxin from the venom of the Malayan krait (Bungarus candidus). Biochem J 2001; 360: 539-548.
162. Hansen AP, Petros AM, Meadows RP, Nettesheim DG, Mazar AP, Olejniczak ET, et al. Solution structure of the amino-terminal fragment of urokinase- type plasminogen activator. Biochemistry 1994; 33: 4847-4864.
163. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Design 2003; 9(19): 1565-74.
164. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Design 2003; 9(19): 1499-528.
165. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Design 2003; 9(19): 1529-43.